Immuneering Q3 net loss widens to $24.2 million; cash runway extended to 2028
Immuneering reported a third-quarter 2026 net loss of $24.2 million, or $0.37 per share, up from $15.0 million in the same quarter of 2025, as research and development spending rose to $20.7 million. The company said its cash runway now extends into the fourth quarter of 2028, but cash, cash equivalents and marketable securities fell to $166.1 million from $217.0 million at December 31, 2025, and the filing reports no revenue.
Key points
- Q3 2026 net loss was $24.2 million ($0.37 per share), versus $15.0 million ($0.38 per share) in Q3 2025.
- R&D expenses were $20.7 million in Q3 2026, compared with $10.9 million a year earlier, citing higher clinical costs and personnel.
- Cash, cash equivalents and marketable securities were $166.1 million at September 30, 2026, down from $217.0 million at December 31, 2025.
- Phase 3 MAPKeeper 301 enrollment target expanded from 510 to 570 patients; the mid-2028 topline readout may be accelerated.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.